Please login to the form below
Orfadin
This page shows the latest Orfadin news and features for those working in and with pharma, biotech and healthcare.
Orphan drug firm Sobi opens new European base
In July the European Commission approved an oral suspension formulation of Orfadin (nitisinone), which treats the rare - and potentially fatal - genetic disease Hereditary Tyrosinaemia type-1 (HT-1). ... More recently the FDA this week began its review
Latest news
-
Sobi wins European approval for oral form of orphan drug Orfadin
Expandstreatment options for rare genetic disease HT-1. . The European Commission has approved an oral suspension formulation of Swedish Orphan Biovitrum's (Sobi) Orfadin (nitisinone). ... An oral suspension of Orfadin for paediatric use will
-
PatientsLikeMe takes aim at one of world's rarest diseases
disease. Although there is currently no cure for AKU, Swedish Orphan Biovitrum's tyrosinaemia treatment Orfadin (nitisinone) is used off-label to treat AKU and is expected to enter phase III
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
Featured jobs
- Account Manager – Healthcare advertising
-
Salary TBC
-
Account Director – UK Office
-
Excellent salary and benefits
Subscribe to our email news alerts
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...
Latest intelligence
- Article: Like, Like, Like: Harnessing the power of social media insights
- ...
- Its Know Your Numbers week
- Do you know yours?...
- What is changing in mental health and dementia care?
- Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services...
Quick links
Infographics
